Table 2.
Mouse pharmacokinetic data for CTCB-405, CTCB-470 and CTCB-508.
| CTCB-405 | CTCB-470 | CTCB-508 | ||||
|---|---|---|---|---|---|---|
| Route | IV | PO | IV | PO | IV | PO |
| Dose (mg kg−1) | 1 | 5 | 1 | 10 | 1 | 10 |
| Elimination t1/2 (h) | 2.7 | 3.1 | 0.7 | |||
| AUC (infinity) (ng-h mL−1) | 260 | 704 | 657 | 1565 | 349 | 4170 |
| Cmax (ng mL−1) | 206 | 393 | 1333 | |||
| Tmax (h) | 0.3 | 0.5 | 2.0 | |||
| Vd (area) (L kg−1) | 12.3 | 6.9 | 2.9 | |||
| CL/kg (L h−1 kg−1) | 3.8 | 1.5 | 2.7 | |||
| Bioavailability (F%) | 54 | 24 | 119 | |||
Pharmacokinetic parameters of the compounds in plasma were calculated from the curves using PKSolutions software. Compounds were administered either intravenously or orally at the doses indicated (n = 1 for each compound). ‘Methods’ are described in Supplementary Methods 6.1 and Supplementary Fig. 9).